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Abstract
Background: The subjective experience of young women with breast cancer has some particular features linked to
the impact of the disease and its treatment on their age-related issues (e.g. desire for a child, couple relationship,
career management). Despite these specific concerns, no questionnaire currently targets the young breast cancer
patient’s quality of life, subjective experience or common problems when facing cancer. This study presents the
psychometric validation of an inventory that aimed to measure the impact of breast cancer on the quality of life of
young women (<45 years of age) with non-metastatic disease.
Methods: 546 women aged <45 years when diagnosed with a non-metastatic breast cancer were recruited in 27
French cancer research and treatment centers. They answered a self-reported questionnaire created from verbatim
collected by non-directive interviews carried out with 69 patients in a first qualitative study. Exploratory and
confirmatory analyses were conducted in order to obtain the final structure of the scale. Internal consistency,
test-retest reliability and concurrent validity with quality of life questionnaires currently used (QLQ-C30 and the
QLQ-BR23 module) were then assessed.
Results: The YW-BCI36 contains 36 items and highlights 8 factors: 1) feeling of couple cohesion, 2) negative affectivity
and apprehension about the future, 3) management of child(ren) and of everyday life, 4) sharing with close relatives,
5) body image and sexuality, 6) financial difficulties, 7) deterioration of relationships with close relatives, and 8) career
management. Psychometric analyses indicated good internal consistency (Cronbach’s alpha values ranging from
0.76 to 0.91) and temporal reliability (Bravais-Pearson correlations ranging from 0.66 to 0.85). As expected, there
were quite strong correlations between the YW-BCI36 and the QLQ-C30 and QLQ-BR23 scores (r ranging from
0.20 to −0.66), indicating adequate concurrent validity.
Conclusions: The YW-BCI36 was confirmed as a valid scale for evaluating the subjective experience of breast cancer
in young women. This instrument could help to identify the problems of these women more precisely, in order to
respond to them better by an optimal care management. This scale may improve the medical, psychological and
social care of breast cancer patients.
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Background
The study of quality of life in the health area has consid-
erably grown in recent decades. Defined by the WHO in
1994, quality of life refers to the “individuals perception
of their position in life in the context of the culture and
value systems in which they live and in relation to their
goals, expectations, standards and concerns ” [1]. This is
above all a measure of quality of life in relation with
health in general, health being defined as a “state of
complete physical, mental, and social well-being, and
not merely the absence of disease” [1]. Well-being is in
turn defined as having two dimensions, subjective and
objective, and “comprises an individual’s experience of
their life as well as in comparison of life circumstances
with social norms and values” [2]. Most authors thus
agree that quality of life is a concept that encompasses
three key dimensions: physical, psychological and social
e.g. [3]. With this conceptual anchor, it therefore seems
essential to take into account the specificities, standards,
environmental and societal values of the health and/or
disease context in which individuals live, in order to
more precisely target the specificities of their subjective
and objective experience.
In oncology, novel therapeutics have greatly improved
the survival rate of women with cancer, but they often
entail significant side effects that worsen the patient’s
physical and psychological quality of life, at every stage
of their care pathway, from the diagnosis announcement
to the follow-up or “survivorship” period [4–6]. Health-
related quality of life (HRQOL) is defined as the phys-
ical, psychological and social responses of the patient
when facing the disease and its treatment [7, 8] as well
as the patient’s subjective perception of the impact of
the cancer and its treatment on different areas of his/her
life: physical, functional, emotional and social [9].
Evaluating quality of life appears crucial in everyday
clinical practice for detecting physical and emotional
problems provoked by the disease or its treatment. This
contributes to improving patients’ care by guiding them,
according to their identified problems and needs, toward
appropriate support care, throughout their care pathway
[7, 10–12]. Every woman suffering from breast cancer
has to face many issues e.g. [13–16], but the conse-
quences of the disease and its treatment are markedly
different and have specific features in young women
(under 45–50 years old at the time of the initial diagno-
sis), who represent almost 13% of diagnosed breast can-
cer cases [17, 18]. Some indicators were identified in the
literature as most useful for using the age criterion of 45
or younger as it applies to breast cancer: the woman is
of child bearing age, the woman has young child(ren),
that is, child(ren) not yet at secondary school; or the
woman is premenopausal [18, 19]. These women are
confronted by issues that are specific to their age, like (i)
the fact that they cannot be sure of seeing their chil-
d(ren) grow up or have problems in bringing them up,
all the more so as their child(ren) is/are very young; (ii)
the quality of their marital relationship and sexuality and
(iii) their current or future professional career for re-
views, see [4, 20–23]. These specific issues, in addition
to the physical consequences of the disease and its treat-
ment, could partly explain why young women show
higher emotional distress levels, less quality of life, and
more problems in setting up adjustment strategies to
face the disease than older women do e.g. [24–28].
The assessment instruments that are most frequently
used, such as the QLQ-C30 coupled with the module es-
pecially developed for breast cancer QLQ-BR23 [29], the
FACT-G coupled with the module FACT-B for breast
cancer [30], or the unmet needs assessment tools for re-
views, see [31, 32], aim to evaluate the quality of life of
women with breast cancer as a whole, whatever their
age. To our knowledge, there is as yet no assessment
tool to evaluate the specific subjective experience of
young women living with breast cancer. Following the
example of some authors [33, 34], it seems crucial to
consider all the life areas that may be affected by the dis-
ease experience, in a given context governed by norms
and specific values. For this, it is essential to have appro-
priate tools, created from the experiences of the patients
themselves -in order to be as close as possible to their
subjective experience-, presenting the required psycho-
metric properties and easily usable by the medical care-
givers in the care pathway. To create such a tool thus
seems particularly relevant for helping clinicians to iden-
tify the issues specific to this population and, using the
results provided by the tool, to guide their patients to-
ward appropriate social support services, at every stage
of their care pathway [12, 31, 35–37].
The present study aims to validate, in a large sample
of patients, a questionnaire specifically measuring the
subjective experience of the disease and its treatment in
young women (under 45 years old when diagnosed) liv-
ing with a non-metastatic breast cancer and the reper-
cussions of the disease and its treatment they perceive in
their daily life. This scale (“Young Women with Breast
Cancer Inventory - YW-BCI”) differs by being created
from non-directive interviews carried out with patients
in a previous qualitative study [38, 39], and by taking into
account the specific features of women facing breast can-
cer at a young age. To better understand the temporal
evolution of the cancer impact from the diagnosis an-
nounce to the follow-up period, four independent groups
of patients were formed: 1. During the chemotherapy with
or without Trastuzumab; 2. Under Trastuzumab with or
without hormone therapy; 3. During the hormone therapy
alone; and 4. During the follow-up period (after the end of
all treatments).
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Methods
Study design and population
Our data are part of an observational prospective multi-
center study conducted from January 2010 to June 2012
in 27 French cancer treatment and research centers and
involving 772 young women with diagnoses of non-
metastatic breast cancer. Out of the 772 patients to
whom the study was proposed, 546 patients agreed to
participate and returned their filled questionnaire (168
undergoing chemotherapy with or without Trastuzumab,
58 undergoing Trastuzumab with or without hormone
therapy, 176 patients undergoing hormone therapy only,
and 144 under follow-up, after the end of treatment).
Patients were included by their oncologist if they were
aged less than 45 years at their diagnosis for a non-
metastatic breast cancer, had received or were receiving
chemotherapy, and had signed an informed consent
form. Patients with poor knowledge of the French lan-
guage were not included in the study.
The objectives and procedure of the study were ex-
plained to the patients during an outpatient appointment.
After they had agreed orally and signed the consent form,
patients received a questionnaire and a socio-demographic
data form. They were asked to complete these documents
in a quiet location and to return them in a pre-stamped
envelope to the research centers. Conditions of anonymity
and confidentiality were guaranteed. At the same time, pa-
tients’ medical data were collected by each investigator in
the participating centers. All women were asked to
complete the YW-BCI. To test concurrent validity, 111
women also answered a standard quality of life question-
naire (QLQ-C30 and QLQ-BR23, [29]). For the reliability
analysis, the YW-BCI was administered two weeks after
the baseline measurement in 116 patients. The distribu-
tion in one of these 3 groups (YW-BCI only, YW-BCI +
QLQ, YW-BCI two times) was randomly made at the time
the patients entered in the study.
This study was performed in accordance with the
Declaration of Helsinki and was approved by the Ethics
Committee for the Protection of Persons, the Consultative
Committee for Data Processing in Research in the Field of
Health, and the National Commission for Data Protection.
Measures
YW-BCI
The YW-BCI scale consists of 80 items resulting from a
previous qualitative study carried out with 69 young pa-
tients (<45 years old at the time of diagnosis) living with
a non-metastatic breast cancer [38, 39]. Items were pro-
duced from a thematic content analysis with inter-judges
agreement and were semantically validated by 15 couples
who participated in these interviews [38, 39].
From this first qualitative step, 80 items were selected
and organized into 8 distinct dimensions: 1) psychological
and affective experience concerning the present and the
future (14 items, e.g. emotions felt, perception of the fu-
ture), 2) physical experience (8 items, e.g. physical side
effects of treatments, fatigue, body image perception), 3)
management of daily life (5 items, e.g. problems in man-
aging housework and daily life, limitations felt in doing
housework, changes in life habits), 4) questions about the
child(ren) (8 items, e.g. problems in managing the educa-
tion of the child(ren), fear for the chil(dren), availability,
communication), 5) professional life (4 items, e.g. sick
leave, personal investment in job, taking days off, effective-
ness at work, career, professional difficulties), 6) financial
difficulties (4 items, e.g. income decrease, problems in get-
ting a loan, additional costs), 7) familial and social rela-
tionships (16 items, e.g. communication, cohesion, social
support, perception of the impact of the disease on rela-
tives and on social activities), and 8) couple relationship
(21 items, e.g. communication, cohesion and social sup-
port within the couple, impact of the disease on the part-
ner, sexuality).
In order to create and validate an inventory that shows
good psychometric properties, the patients in the
present study were instructed to indicate to what extent
each of the 80 assertions corresponded to their current
state (“at this moment, currently”), using a 5-point Likert
scale, from 1: “strongly disagree” to 5: “strongly agree”.
EORTC QLQ-C30
In order to test the concurrent validity of the YW-BCI,
the patients were invited to complete the French version
of the EORTC QLQ-C30 (version 3, [29]).This self-
reported questionnaire aims to evaluate the health-
related quality of life of cancer patients, whatever the
cancer site, using 2 dimensions: the overall functioning
and the symptoms felt. In line with the EORTC guide-
lines, each score was linearly transformed, so that it var-
ied from 0 to 100. The higher the functioning scale
score is, the better the functioning level of the patient is.
On the contrary, an elevated score on the symptoms
scale indicates a greater presence of symptoms.
EORTC QLQ-BR23
The patients were also invited to complete the EORTC
QLQ-BR23, a module developed to assess the particular
features of the quality of life of breast cancer patients.
This module contains 23 items that enable the repercus-
sions of the disease and the side effects of its treatment
to be measured. For each dimension, the scores vary
from 0 to 100. As for the EORTC QLQ-C30, a high
score on the functioning scale indicates a high level of
functioning, whereas for the symptoms scale, a high
score indicates a high level of symptoms.
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Statistical analysis
The construct validity of the scale was assessed by ex-
ploratory and confirmatory analyses. The exploratory
principal component analysis (PCA) were conducted on
a sample of 304 patients, randomly chosen from the 546
patients who completed the instrument. The confirma-
tory analyses (CFA) were carried out on a random sam-
ple of 250 patients from this initial sample.
Descriptive analyses (mean, standard deviation, skew-
ness and kurtosis) were conducted first, in order to elimin-
ate the poorly discriminative items (n = 14). Exploratory
principal component analyses using the principal axis fac-
toring method of extraction and Promax rotation were
then conducted with the Statistical Package for Social Sci-
ences Version 18 to identify the factor structure of the
scale. At this step, items showing cross-loadings or load-
ings less than 0.30 were eliminated (n = 32). Items were
thus selected with factor loadings of at least 0.30. Series of
confirmatory factor analyses based on a structural equa-
tion modeling method were then conducted on the
retained items, with LISREL 8.8 software [40].
Internal consistency was examined for each subscale
of the YW-BCI by using Cronbach’s alpha coefficients.
Test-retest reliability was investigated using the Bravais-
Pearson’s correlation coefficient for the sample of patients
(n = 116) who completed the YW-BCI questionnaire twice.
The convergent validity of our scale was assessed by
calculating the Bravais-Pearson’s correlation coefficients
between the patients’ scores in the YW-BCI and their
scores in the QLQ-C30 and QLQ-BR23. Given that they
were subjective quality of life constructs, quite strong
correlations were expected between the subjective di-
mensions of quality of life measured by the QLQ-C30
and QLQ-BR23 (emotional functioning, social function-
ing, etc.) and the subjective dimensions that constitute the
YW-BCI (Pearson’s r > 0.50). Weaker correlations were ex-
pected between these subjective dimensions and the qual-
ity of life dimensions involving the physical consequences
of the disease and its treatment (Pearson’s r < 0.40).
Results
Sample characteristics
The sample included 546 young women, aged 23–62
(M = 40.64, SD = 6.21). On average, patients who partici-
pated in the study had suffered from breast cancer for
2.47 years (SD = 2.79, time since diagnosis ranging from
21 days (Min) to 19.05 years (Max)). The majority of pa-
tients had a job (88.8%), more than half of them were on
sick leave or were working part-time for medical reasons
when the study was carried out. Almost half of them had
post-secondary education or higher education qualifications
(48.79%). The majority of the patients (97.80%) were living
in a couple at the time of diagnosis (Myears= 13.71, SD =
8.37 years), and had a child or children (88.6%) (Table 1).
At the medical level, for most patients it was their first
cancer (94.7%), 91.4% had had a mastectomy: 62.3% had
had a partial mastectomy with axillary node dissection
for 71.9% of them while 42.7% of the patients had had a
total mastectomy. For 61.97% of these patients who had
had a total mastectomy, a delayed reconstruction was
planned. Lastly, 74 patients had participated in psycho-
therapy when the study was conducted, and 148 patients
had received antidepressants or anxiolytic drugs.
Factor structure of the YW-BCI questionnaire
Exploratory analyses
A structure of 8 factors emerged from the exploratory
principal component analysis which was preceded by the
analysis of the graph of eigenvalues -for determining the
optimal number of dimensions-, and the theoretical rele-
vance of the constructs that appeared. These factors ex-
plained 57.24% of the total variance and were as follows:
1) feeling of couple cohesion (19.78% of the total vari-
ance), 2) negative affectivity and apprehension about the
future (12.52%), 3) management of child(ren) and of
everyday life (7.81%), 4) sharing with close relatives
(4.83%), 5) body image and sexuality (4.41%), 6) finan-
cial difficulties (3.17%), 7) deterioration of relationships
with close relatives (2.46%), and 8) career management
(2.25%) (Table 2).
The final inventory, “YW-BCI36”, thus contained 36
items. The dimensions relating to psychological and
affective experience concerning the present and the fu-
ture, management of daily life, now completed by items
linked with questions about the child(ren), professional
life and financial difficulties, which were present in the
initial version of the questionnaire, still remained. The
dimension in line with social and familial relationships
was split into two parts, depending on the positive or
negative valence of the interpersonal relationships: a first
dimension that was linked with social sharing, and a sec-
ond dimension that was in line with the deterioration of
relationships with close relatives. Likewise, two dimen-
sions emerged related to the couple: couple cohesion,
with items linked with support and closeness, and body
image and sexuality with items that were more linked
with couple intimacy.
These dimensions appeared to be intercorrelated
(Table 3). Like for the majority of health-related quality of
life questionnaires, the correlations were quite strong be-
tween the subscales and particularly for the negative
affectivity and apprehension about the future and manage-
ment of the child(ren) and of everyday life dimensions.
Confirmatory analyses
The structure thus revealed was supported by the con-
firmatory factor analyses conducted on data from a ran-
dom sample of 120 patients. The results generally
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suggested a good adjustment of the model ((χ2(585) =
987.793; p < 0.001; χ2/ddl = 1.68; RMSEA = 0.047; NFI =
0.91; SRMR = 0.070 ; NNFI = 0.96)
Internal consistency and test-retest reliability
Cronbach’s alphas (Table 4) were acceptable overall in
light of the number of items composing the subscales of
the questionnaire (all were higher than 0.75, ranging
from 0.76 to 0.91). The Bravais-Pearson’s correlation co-
efficients between the scores of the 116 patients who
completed the questionnaire twice (mean time between
Table 1 Patients characteristics (N = 546)
Demographics
Age (Range, Mean, SD) 23-62 (40.64, 6.21)
Employment
Farmers 5
Craftspersons, shopkeepers, company managers 28
Executives and intellectual professions 69
Intermediate professions 106
Employees 253
Workers 17
Retired 2
Unemployed 58
Missing 8
Education
No certificate 34
Secondary education diploma –
below baccalaureate
129
Baccalaureate or equivalent diploma 114
First undergraduate cycle degree or
equivalent diploma
119
Second university cycle degree, doctorate
or equivalent diploma
145
Missing 5
Presence of child(ren) 484
Length of the relationship (in years): Mean (SD) 13.71 (8.37)
Disease and treatments characteristics
Event type
First breast cancer 517
Local recurrence 14
Contralateral cancer 13
Missing 2
Time since diagnosis (in years): Mean (SD) 2.47 (2.79)
Treatment for the current eventa
Surgery
Yes 499
No but planned 42
No 5
Partial mastectomy 311
Total mastectomy 213
Immediate reconstruction 21
Delayed reconstruction 132
Unwanted reconstruction 17
Unknown 11
sentinel lymph node biopsy 160
axillary lymph node dissection 359
Radiotherapy
Yes 343
Table 1 Patients characteristics (N = 546) (Continued)
No but planned 142
No 50
Missing 11
Trastuzumab
Yes 134
No but planned 11
No 397
Missing 4
Hormone therapy
Yes 251
No but planned 131
No 163
Missing 1
Tamoxifen 229
Gonadotropin-Releasing Hormone (GnRH) 29
Aromatase inhibitors 29
Psychotherapy
Yes 74
No 466
Missing 6
Antidepressants or anxiolytic drugs
Yes 148
No 394
Missing 4
Sick leave
Yes 236
No 282
Non applicable 23
Working part-time for medical reasons
Yes 28
No 481
Non applicable 29
Missing 8
aAll the patients were or had been undergoing chemotherapy at the time of
the study
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Table 2 Factor structure of the questionnaire (loadings)
Items Feeling of
couple cohesion
Negative affectivity
and apprehension
about the future
Management
of child(ren)
and of
everyday life
Sharing with
close relatives
Body image
and sexuality
Financial
difficulties
Deterioration of
relationships with
close relatives
Career
management
I feel close to my partner. (Je me sens proche
de mon (ma) partenaire)
0.920
My couple is strong. (Mon couple est uni) 0.895
I feel supported by my partner. (Je me sens soutenue
par mon (ma) partenaire)
0.850 −0.266
My partner helps me a lot. (Mon (ma) partenaire
m’aide beaucoup)
0.785 −0.296
I can confide in my partner. (Je peux me confier à
mon (ma) partenaire)
0.718
I feel worried. (Je me sens inquiète) 0.826 0.244
I have anxieties. (J’ai des angoisses) 0.794
I’m concerned about the future. (L’avenir me préoccupe) 0.639
I am calm. (Je suis sereine) (R) −0.637 −0.369 −0.339 −0.388
I think about my disease every day. (Je pense tous les
jours à la maladie)
0.543 0.312
I am afraid for my child(ren). (J’ai peur pour mon (mes)
enfant(s))
0.533
I have trouble taking care of the home. (J’ai des
difficultés pour m’occuper du logement)
0.315 0.810 0.339 0.262 0.327
I have problems managing daily life with my child(ren).
(J’ai des difficultés dans la gestion du quotidien avec
mon (mes) enfant(s))
0.347 0.753 0.345 0.383
I feel that I’m neglecting managing daily life.
(J’ai l’impression de négliger la gestion du quotidien)
0.301 0.663 0.311 0.353 0.387
I delegate most daily tasks. (Je délègue la majorité des
tâches du quotidien)
0.644 0.313 0.351
I have problems managing the education of my child(ren).
(J’ai des difficultés à gérer l’éducation de mon (mes) enfant(s))
0.606 0.204 0.289
I can confide in some people. (Je peux me confier à
certaines personnes)
0.791 −0.327
Some people around me help me a lot. (Certaines personnes
de mon entourage m’aident beaucoup)
0.788 −0.311
I talk about my disease with those around me. (Je discute
de la maladie avec mon entourage)
0.772
I talk about how I feel with some of my close relatives.
(Je parle de ce que je ressens à certains de mes proches)
0.677
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Table 2 Factor structure of the questionnaire (loadings) (Continued)
I feel less sexual desire. (Je ressens moins de désir sexuel) 0.329 0.823
I have some sexual problems because of my disease.
(Je rencontre des difficultés sexuelles à cause de la maladie)
0.809
I have trouble letting my partner touch me physically.
(J’ai des difficultés à accepter que mon (ma) partenaire
me touche physiquement)
0.319 0.682
I feel that I’m neglecting my partner. (J’ai l’impression
de délaisser mon (ma) partenaire).
−0.305 0.358 0.676
I have problems dealing with the costs incurred by my
disease. (J’ai des difficultés pour faire face aux frais
engendrés par la maladie)
0.311 0.256 0.858 0.376
I have financial difficulties. (J’ai des difficultés financières) 0.303 0.753
My disease causes additional costs. (La maladie occasionne
des frais supplémentaires)
0.399 0.665 0.356
I have to reduce my lifestyle. (Je dois diminuer mon train de vie) 0.301 0.205 0.510 0.261
I can count on those around me. (Je peux compter sur
ceux qui m’entourent) (R)
0.302 0.331 −0.686
I feel neglected by some of my close relatives. (Je me sens
délaissée par certains de mes proches).
−0.313 0.665
My disease creates tensions with the people around me.
(La maladie crée des tensions avec les personnes qui m’entourent)
0.308 0.306 0.327 0.344 0.597
I have problems communicating with some of my close
relatives. (J’ai des problèmes de communication avec
certains de mes proches)
−0.372 0.376 −0.339 0.589
My disease has a negative impact on my close relatives.
(La maladie a un impact négatif sur mes proches)
0.522
I feel that I’m effective at work. (Je me sens efficace
dans mon activité professionnelle) (R)
−0.392 −0.327 −0.820
I have problems doing my job. (J’ai des difficultés à
exercer mon activité professionnelle).
0.377 0.392 0.815
I put a lot into my work. (Je m’investis dans mon travail) (R) −0.381 −0.790
% of variance before rotation 7.12 4.508 2.81 1.74 1.59 1.14 0.884 0.812
% of variance after rotation 19.78 12.52 7.81 4.83 4.41 3.17 2.46 2.25
% added up after rotation 19.78 32.31 40.11 44.94 49.356 52.53 54.98 57.24
Loadings and proportions of variance reported are from a Principal Component Analysis (PCA) and Promax method for rotation. Loadings above 0.30 are shown in boldface. For the sake of readability, loadings below
0.20 are not shown
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the two completions: 16.57 days, SD = 5.03) showed that
the test-retest reliability of the questionnaire was accept-
able, with correlation coefficients ranging from 0.66 (for
the dimension sharing with close relatives) to 0.85 (feel-
ing of couple cohesion, Table 4).
Concurrent validity
The financial difficulties dimension of the YW-BCI36
was strongly and positively correlated with the financial
difficulties item of the QLQ-C30 (r = 0.73, p < 0.001) and
the negative affectivity and apprehension about the fu-
ture dimension of our scale was correlated with the emo-
tional functioning dimension of the QLQ-C30 (r = −0.59,
p < 0.001), suggesting that both questionnaires examined
dimensions close to each other. The management of
child(ren) and of everyday life dimension was further
correlated with the social functioning dimension of the
QLQ-C30 (r = −0.62, p < 0.001). Concerning the concurrent
validity of the YW-BCI36 with the QLQ-BR23 module, the
body image and sexuality dimension of the YW-BCI36 was
correlated with the sexual functioning, sexual enjoyment,
and body image subscales of the module, at −0.74, −0.65,
and −0.41, respectively (p < 0.001), which indicated a fair
convergence between these factors. In the same way, the
negative affectivity and apprehension about the future sub-
scale of the YW-BCI36 was negatively and moderately
correlated with the future perspective dimension of the
QLQ-BR 23 (r= −0.66, p < 0.001), see Table 5.
Concerning the concurrent validity with the symptoms
scales, the results mainly evidenced positive and quite
strong correlations between problems in the manage-
ment of the child(ren) and of everyday life in the YW-
BCI36 and almost all the symptoms, as well as negative
correlations between some symptoms (fatigue, pain, dys-
pnea) assessed by the QLQ-C30 and difficulties in the
career management dimension of the YW-BCI36
(Table 5). Lastly, concerning the correlations between
the YW-BCI36 dimensions and the symptoms subscales
of the QLQ-BR23, the problems of body image and
sexuality were negatively correlated with the fact of be-
ing upset by hair loss, while the problems in the man-
agement of child(ren) and of everyday life were positively
linked with the therapy side effects (Table 5).
Divergent validity
Results showed only one weak correlation between the
sharing with close relatives dimension of the YW-BCI36
and the QLQ-C30 and QLQ-BR23 dimensions (emo-
tional functioning, r = 0.21), revealing divergent validity
in aspects linked with social interactions. Similarly, the
deterioration of the relationships with close relatives
dimension of the YW-BCI36 showed few and weak cor-
relations with the QLQ-BR23 subscales. None of the
YW-BCI36 dimension appeared correlated with sub-
scales evaluating specific physical effect sides of the
treatments (diarrhea and arm symptoms subscales of the
QLQ-BR23) (Table 5).
In summary, as expected we found more correlations
(ranging from 0.20 to −0.66) between the dimensions
linked with the functioning -whether in the QLQ-C30 or
Table 3 Correlations between the 8 dimensions of the factor structure of the questionnaire
1 2 3 4 5 6 7 8
F1. Feeling of couple cohesion -
F2. Negative affectivity and apprehension about the future −0.19 -
F3. Body image and sexuality −0.33** 0.44** -
F4. Career management 0.08 −0.29** −0.30** -
F5. Deterioration of relationships with close relatives −0.36** 0.38** 0.35** −0.22* -
F6. Management of child(ren) and of everyday life −0.14 0.34** 0.42** −0.49** 0.39** -
F7. Financial difficulties −0.16 0.33** 0.30** −0.39** 0.37** 0.48** -
F8. Sharing with close relatives 0.23* −0.17 −0.17 −0.11 −0.37** −0.05 −0.06 -
Bravais-Pearson’s r (N = 436). Correlations in boldface p < 0.001
Table 4 Internal consistency (Cronbach’s alpha) and test-retest
reliability (Bravais-Pearson coefficient) of the questionnaire
Number of items Alpha R
Feeling of couple cohesion 5 0.91 0.85
Negative affectivity and apprehension
about the future
6 0.84 0.80
Body image and sexuality 4 0.82 0.85
Career management 3 0.85 0.77
Deterioration of relationships
with close relatives
5 0.76 0.80
Management of child(ren) and
of everyday life
5 0.81 0.79
Financial difficulties 4 0.80 0.82
Sharing with close relatives 4 0.83 0.66
For the test-retest reliability, all the correlations are significant at p < 0.01, n = 116
patients for whom the period between T1 and T2 was less than or equal to
1 month
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in the QLQ-BR23 module- and the subjective dimen-
sions of the YW-BCI, in particular the management of
child(ren) and of everyday life and financial difficulties
dimensions. Less correlations were showed between the
symptom dimensions of the QLQ-C30 and QLQ-BR23
and the dimensions of the YW-BCI36 (correlations ran-
ging from −0.22 to 0.58).
Discussion
The main objective of the present study was to validate,
in the French language, a new assessment tool for the
impact of non-metastatic breast cancer on the subjective
experience of young women (aged under 45 years),
which was created from the results of a previous qualita-
tive study [38, 39]. While many studies have already fo-
cused on the quality of life of women with breast cancer
e.g. [4, 5, 26, 41], taking into account the particular case
of young women who have to face specific issues appears
crucial for their care.
Following the results of exploratory and confirmatory
analyses, the final version of the YW-BCI36 inventory
contains 36 items that evaluate 8 types of consequences
of the disease and its treatment in terms of impact on
daily life for young women living with non-metastatic
breast cancer: 1) feeling of couple cohesion (5 items), 2)
negative affectivity and apprehension about the future
(6 items), 3) management of child(ren) and of everyday
life (5 items), 4) sharing with close relatives (4 items), 5)
body image and sexuality (4 items), 6) financial difficul-
ties (4 items), 7) deterioration of relationships with close
relatives (5 items), 8) career management (3 items). This
8-factor structure explains 57% of the variance and our
Table 5 Convergent validity of the YW-BCI36 with the functioning and symptoms scales of the QLQ-C30 and QLQ-BR23
Dimensions of
the YW-BCI36
Feeling of
couple cohesion
Negative affectivity
and apprehension
about the future
Body image
and sexuality
Career
management
Deterioration of
relationships with
close relatives
Management of
child(ren) and
of everyday life
Financial
difficulties
Sharing
with close
relatives
EORTC QLQ-C30 functioning
Overall health status 0.28* −0.36** −0.35** 0.61** −0.35** −0.63** −0.43** 0.14
Physical functioning 0.16 −0.22* −0.33** 0.52** −0.32** −0.60** −0.45** 0.08
Role functioning 0.14 −0.31** −0.15 0.51** −0.24* −0.58** −0.34** −0.02
Emotional functioning 0.21* −0.59** −0.41** 0.28* −0.35** −0.50** −0.35** 0.21*
Cognitive functioning 0.35** −0.27* −0.20* 0.33** −0.33** −0.53** −0.30** 0.05
Social functioning 0.20* −0.30** −0.29** 0.48** −0.30** −0.62** −0.46** −0.01
Financial difficulties −0.28* 0.02 0.11 −0.42** 0.05 0.28** 0.73** 0.14
QLQ-BR23 functioning
Body image 0.12 −0.41** −0.41** 0.39** −0.19 −0.31* −0.31* 0.14
Sexual functioning 0.51** −0.37** −0.74** 0.29* −0.17 −0.33 0.04 0.05
Sexual enjoyment 0.03 −0.33** −0.65** 0.23* −0.48** −0.43** −0.07 0.27
Future perspective 0.11 −0.66** −0.32* 0.16 −0.21* −0.25 −0.13 0.16
QLQ-C30 symptoms
Fatigue −016 0.31** 0.32** −0.53** 0.20* 0.58** 0.52** 0.02
Nausea and vomiting −0.22* 0.23* 0.18 −0.22* 0.13 0.35** 0.24* 0.04
Pain −0.07 0.26* 0.18 −0.37** 0.19 0.51** 0.42** 0.02
Dyspnea −0.01 0.09 0.02 −0.36** 0.19 0.29** 0.19 −0.19
Insomnia −0.21* 0.42** 0.35** −0.17 0.28* 0.46** 0.26** −0.16
Appetite loss −0.13 0.31** 0.33** −0.26* 0.16 0.45** 0.33** 0.04
Constipation −0.02 0.24* 0.25** −0.24* 0.12 0.16 0.07 −0.10
Diarrhea −0.10 0.18 0.10 −0.10 0.06 0.15 0.05 0.001
QLQ-BR23 symptoms
Systemic therapy side
effects
−0.08 0.37** 0.22 −0.49** 0.08 0.42** 0.35* 0.11
Breast symptoms −0.49** 0.38** 0.21 −0.39** 0.37** 0.17 0.08 0.23
Arm symptoms 0.11 −0.09 −0.19 - −0.22 −0.05 0.10 0.17
Upset by hair loss −0.11 0.27* 0.39** −0.18 −0.03 0.03 0.08 0.11
*p < 0.01; **p < 0.001
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study confirms that the YW-BCI36 shows acceptable psy-
chometric properties, with a high level of reliability and
validity. There is good internal consistency (above 0.75),
and the temporal stability indices are higher than 0.75 for
the majority of dimensions. Convergent validity indicates
correlations with comparable tools (QLQ-C30 and QLQ-
BR23), which is consistent with our hypotheses.
The YW-BCI36 therefore should be considered a com-
plement to existing tools as it addresses not only similar
dimensions, but also very specific dimensions, with more
precise and targeted item formulations, such as the is-
sues concerning the management of child(ren) in every-
day life, positive and negative social relationships with
close relatives, and the relationship within the couple.
On the other hand, issues concerning symptoms are little
depicted in the YW-BCI36 whereas strong correlations are
evidenced between its management of child(ren) and of
everyday life and career management dimensions and the
symptoms subscales in the QLQ-C30 and QLQ-BR23. Fu-
ture studies should certainly consider these links in order
to refine their determinants and causalities.
The YW-BCI36 was created from the young women’s
own subjective experience in order to assess subtly their
preoccupations and was validated with a large sample of
patients. It makes it possible to identify not only the po-
tential problems of these patients, but also their points
of reference/protecting factors, which could help avoid
or at least mitigate the impact of the disease and its
treatment. This is especially true for dimensions that are
related to the sense of cohesion in the couple and to the
sharing with close relatives, which appear crucial for the
patients’ adjustment when facing cancer e.g. [42–45].
Like the other instruments addressing the quality of
life, the YW-BCI36 used in follow-up consultations
could also offer patients the opportunity to discuss the
issues and challenges that are relevant to them and for
which they require psychological and/or medical sup-
port. Another advantage of the questionnaire is that it
was created and validated with patients at all stages of
the care pathway. Among the items that were retained
following the patient interviews and psychometric ana-
lyses, none is specific to a particular treatment stage,
and thus this inventory can be offered to any young
woman diagnosed with breast cancer.
Many studies have shown it is relevant to evaluate the
quality of life of patients all along the care pathway for
modifying their medical care in accordance with their
identified needs e.g., [11, 12, 46, 47]. It seemed all the
more relevant to create a tool targeting young women
with breast cancer to adjust their medical care through
an acute evaluation of their subjective experience of the
disease and treatments. In addition to its use in the
medical practice –allowed by its relatively short form-
such a tool could also be used in studies searching to
highlight some of the determinants of the quality of life
and of its evolution along the care pathway and during
the survivorship period in these women.
Nevertheless, future studies should be conducted in a
longitudinal design, from the diagnosis announcement
to the follow-up period, in order to confirm the stability
of the scale and to understand the time evolutions that
are closely linked with the situation of each patient dur-
ing her therapeutic journey. It would also be very inter-
esting to assess the practical and clinical implications of
this tool’s use in terms of adapted and personalized
support care.
Conclusions
The YW-BCI36 is a valid measure of the impact of non-
metastatic breast cancer on the subjective experience of
young women (aged under 45 years). It can be offered to
any young woman diagnosed with breast cancer to as-
sess subtly her preoccupations and help the clinicians to
improve her care by guiding her toward appropriate sup-
port care, throughout her care pathway. The question-
naire is available on request.
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